Re­se­arch | 22 Juli 2026 11:00

Ori­gi­nal-Re­se­arch: Ad­van­ced Block­chain AG – from GBC AG

22.07.2026 / 11:00 CET/CEST
Dis­se­mi­na­ti­on of a Re­se­arch, trans­mit­ted by EQS News – a ser­vice of EQS Group.
The is­suer is so­le­ly re­spon­si­ble for the con­tent of this re­se­arch. The re­sult of this re­se­arch does not con­sti­tu­te in­vest­ment ad­vice or an in­vi­ta­ti­on to con­clude cer­tain stock ex­ch­an­ge tran­sac­tions.


Clas­si­fi­ca­ti­on of GBC AG to Ad­van­ced Block­chain AG

Com­pa­ny Name: Ad­van­ced Block­chain AG
ISIN: DE000A0M93V6
Re­ason for the re­se­arch: Re­se­arch Re­port (Anno)
Re­com­men­da­ti­on: Buy
Tar­get pri­ce: 2.00 EUR
Tar­get pri­ce on sight of: 31.12.2027
Last ra­ting ch­an­ge:
Ana­lyst: Mat­thi­as Greif­fen­ber­ger, Cos­min Fil­ker

Ba­lan­ce sheet ad­jus­t­ment com­ple­ted. ABAG 2.0 Awaits Ope­ra­tio­nal Pro­of.

Ad­van­ced Block­chain AG (ABAG) con­tin­ued its far-rea­ching ba­lan­ce sheet re­set in fis­cal year 2025. While the pa­rent company’s re­ve­nue rose to €0.31 mil­li­on from €0.23 mil­li­on in the pri­or year, the ope­ra­ting cost base re­main­ed high. EBITDA de­te­rio­ra­ted to -€1.67 mil­li­on from -€1.29 mil­li­on in the pri­or year, while EBIT fell to -€3.36 mil­li­on from -€1.46 mil­li­on in the pri­or year due to high im­pair­ment char­ges. On the bot­tom line, the net loss for the year in­creased to -€3.48 mil­li­on, com­pared to -€1.78 mil­li­on in fis­cal year 2024. Ear­nings were the­r­e­fo­re once again si­gni­fi­cant­ly af­fec­ted by le­gal­ly re­qui­red re­view and re­me­dia­ti­on work, le­gal and con­sul­ting ex­pen­ses, and ex­ten­si­ve ne­ces­sa­ry ba­lan­ce-sheet ad­jus­t­ments.

The most si­gni­fi­cant im­pact oc­cur­red at the sub­si­dia­ry In­c­re­du­lous Labs Ltd., whe­re a lar­ge por­ti­on of the in­vest­ment and to­ken port­fo­lio is con­cen­tra­ted. In 2025, In­c­re­du­lous Labs ge­ne­ra­ted re­ve­nue of $0.05 mil­li­on, down from $0.23 mil­li­on in the pri­or year, and re­por­ted a net loss of $16.98 mil­li­on, com­pared to an ad­jus­ted net pro­fit of $0.95 mil­li­on in the pri­or year. This was pri­ma­ri­ly due to ex­ten­si­ve im­pair­ment char­ges on in­tan­gi­ble as­sets and to­ken rights, fair va­lue los­ses on un­lis­ted pro­ject in­vest­ments, as well as wri­te-offs and al­lo­wan­ces for doubtful ac­counts. As a re­sult, In­c­re­du­lous Labs’ to­tal as­sets fell si­gni­fi­cant­ly to USD 5.39 mil­li­on from USD 21.64 mil­li­on in the pri­or year, while equi­ty de­cli­ned to ne­ga­ti­ve USD 7.48 mil­li­on from po­si­ti­ve USD 9.50 mil­li­on. While this de­ve­lo­p­ment si­gni­fi­cant­ly im­pacts the company’s ba­lan­ce sheet ra­ti­os in the short term, it also crea­tes a much more con­ser­va­ti­ve start­ing point for fu­ture va­lua­ti­on.

On a po­si­ti­ve note, si­gni­fi­cant pro­gress was made in the fis­cal year 2025 in ad­dres­sing his­to­ri­cal is­sues and im­pro­ving go­ver­nan­ce and con­trol struc­tures. The au­di­tor in Cy­prus as­ses­sed the fur­ther de­ve­lo­p­ment of the con­trol sys­tems not me­re­ly as iso­la­ted im­pro­ve­ments, but as a com­pre­hen­si­ve trans­for­ma­ti­on. Thanks to the ex­ten­si­ve as­set pro­tec­tion me­a­su­res con­tin­ued th­roug­hout 2025 and bey­ond, the sys­te­ma­tic re­view of his­to­ri­cal tran­sac­tions, and the com­pre­hen­si­ve op­ti­miza­ti­on of in­ter­nal con­trol and re­con­ci­lia­ti­on pro­ces­ses, the is­sues that had led to the dis­clai­mer of opi­ni­on on In­c­re­du­lous Labs’ 2023 and 2024 fi­nan­cial state­ments were sub­stan­ti­al­ly re­sol­ved. As a re­sult, In­c­re­du­lous Labs was no lon­ger is­sued a dis­clai­mer of opi­ni­on for the 2025 fis­cal year, but ra­ther a qua­li­fied opi­ni­on. The re­mai­ning qua­li­fi­ca­ti­on pri­ma­ri­ly re­la­tes to an in­tra-group ba­lan­ce with Brain Net­works Ltd. In our view, this re­flects si­gni­fi­cant qua­li­ta­ti­ve pro­gress com­pared to pre­vious ye­ars and streng­thens the Group’s trans­pa­ren­cy and ca­pi­tal mar­ket via­bi­li­ty. At the same time, the fi­nan­cial si­tua­ti­on re­mains strai­ned. As of De­cem­ber 31, 2025, Ad­van­ced Block­chain AG had cash and cash equi­va­lents of only €0.11 mil­li­on, while In­c­re­du­lous Labs re­por­ted bank ba­lan­ces of only ap­pro­xi­m­ate­ly $3,700. Af­ter the ba­lan­ce sheet date, the li­qui­di­ty base was streng­the­ned by a six-fi­gu­re share­hol­der loan. Ho­we­ver, fur­ther fi­nan­cing me­a­su­res and the suc­cessful mo­ne­tiza­ti­on of port­fo­lio as­sets re­main key pre­re­qui­si­tes for im­ple­men­ting the new stra­tegy and achie­ving the Group’s sus­tainable sta­bi­liza­ti­on.

Stra­te­gi­cal­ly, the com­pa­ny is now poi­sed to tran­si­ti­on from ba­lan­ce sheet res­truc­tu­ring to ope­ra­tio­nal va­lue crea­ti­on. Un­der the “ABAG 2.0” vi­si­on, the exis­ting in­vest­ment mo­del is to be ex­pan­ded to in­clude the are­as of In­vest­ments, Tre­asu­ry, In­no­va­ti­on, Con­sul­ting, and Ana­ly­tics. Ad­di­tio­nal re­ve­nue po­ten­ti­al is ex­pec­ted to be tap­ped pri­ma­ri­ly th­rough ABX Ana­ly­tics, to­ke­niza­ti­on pro­jects, the use of the tra­ding li­cen­se in Dubai/UAE, and sel­ec­ti­ve ac­ti­vi­ties in AI- and ro­bo­tics-re­la­ted are­as. In the short term, we do not yet ex­pect any ma­te­ri­al ear­nings con­tri­bu­ti­ons from the­se in­itia­ti­ves, but we see meaningful stra­te­gic op­tio­na­li­ty. At the same time, the port­fo­lio stra­tegy is li­kely to fo­cus more stron­gly on a few core po­si­ti­ons with hig­her va­lue app­re­cia­ti­on po­ten­ti­al, in­clu­ding, in par­ti­cu­lar, PEAQ, Pan­op­tic, zCloak/Starks Net­work, and other sel­ec­ted DeFi, in­fra­struc­tu­re, and De­PIN po­si­ti­ons.

We con­ti­nue to con­sider an ad­jus­ted NAV ap­proach ap­pro­pria­te for va­lua­ti­on. Tra­di­tio­nal mul­ti­ples are curr­ent­ly of li­mi­t­ed use due to the lack of a nor­ma­li­zed ear­nings base. Ba­sed on the fair va­lues re­co­gni­zed on the ba­lan­ce sheet, the re­mai­ning to­ken and pro­ject rights, a risk-ad­jus­ted va­lua­ti­on for PEAQ, and a li­mi­t­ed op­ti­on va­lue for ABAG 2.0, we cal­cu­la­te a risk-ad­jus­ted gross as­set va­lue of €14.70 mil­li­on. Af­ter de­duc­ting ex­ter­nal ob­li­ga­ti­ons, fi­nan­cing dis­counts, and ca­pi­ta­li­zed hol­ding cos­ts, the ad­jus­ted NAV amounts to €8.12 mil­li­on. With 4.06 mil­li­on out­stan­ding shares, this cor­re­sponds to a fair va­lue of €2.00 per share.

The stock re­mains a spe­cu­la­ti­ve in­vest­ment with heigh­ten­ed de­pen­dence on to­ken mar­kets, port­fo­lio mo­ne­tiza­ti­on, fi­nan­cing op­por­tu­ni­ties, and the suc­cessful im­ple­men­ta­ti­on of the new ope­ra­tio­nal stra­tegy. At the same time, fol­lo­wing the ba­lan­ce sheet re­set, im­pro­ved con­trol struc­tures, and a stron­ger fo­cus on sel­ec­ted va­lue dri­vers, we see an im­pro­ved foun­da­ti­on for a po­ten­ti­al reva­lua­ti­on. Ba­sed on our op­ti­mi­stic ad­jus­ted NAV mo­del, we the­r­e­fo­re as­sign a BUY ra­ting with a pri­ce tar­get of €2.00.

You can down­load the re­se­arch here: 20260721_Anno_ABAG_EN

Cont­act for ques­ti­ons:
GBC AG
Hal­der­stras­se 27
86150 Augs­burg
0821241133 0
research@​gbc-​ag.​de
++++++++++++++++
Dis­clo­sure of po­ten­ti­al con­flicts of in­te­rest pur­su­ant to Sec­tion 85 of the Ger­man Se­cu­ri­ties Tra­ding Act (WpHG) and Ar­tic­le 20 of the Mar­ket Ab­u­se Re­gu­la­ti­on (MAR) The fol­lo­wing po­ten­ti­al con­flict of in­te­rest exists in re­la­ti­on to the com­pa­ny ana­ly­sed abo­ve: (5a,11); A list of po­ten­ti­al con­flicts of in­te­rest can be found at: https://​www​.gbc​-ag​.de/​d​e​/​O​f​f​e​n​l​e​g​ung
+++++++++++++++
Com­ple­ted: July 21, 2026 (2:00 p.m.)
First re­lease: July 22, 2026 (11:00 a.m.)

Ori­gi­nal-Re­se­arch: Fin­exi­ty AG (by GBC AG): Buy

GBC AG
Hal­der­stra­ße 27
86150 Augs­burg

Te­le­fon: +49 821 241133–0
E‑mail: office(@)gbc-ag.de